Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings
Abstract Background The RAS family protooncogenes, including KRAS, NRAS and HRAS, encode proteins responsible for the regulation of growth, differentiation and survival of many cell types. The HRAS and KRAS oncogene mutations are well defined, however, the clinical significance of RAS expressions in...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-021-07858-w |
| _version_ | 1818611586668953600 |
|---|---|
| author | Milena Pązik Katarzyna Michalska Marta Żebrowska-Nawrocka Izabela Zawadzka Mariusz Łochowski Ewa Balcerczak |
| author_facet | Milena Pązik Katarzyna Michalska Marta Żebrowska-Nawrocka Izabela Zawadzka Mariusz Łochowski Ewa Balcerczak |
| author_sort | Milena Pązik |
| collection | DOAJ |
| description | Abstract Background The RAS family protooncogenes, including KRAS, NRAS and HRAS, encode proteins responsible for the regulation of growth, differentiation and survival of many cell types. The HRAS and KRAS oncogene mutations are well defined, however, the clinical significance of RAS expressions in non–small-cell lung cancer (NSCLC) is still uncertain. Methods A total of 39 whole blood samples of NSCLC (the investigated group), collected at three points of time: at the time of diagnosis, 100 days and 1 year after the surgery as well as 35 tissue samples obtained during the surgery were included in this study. HRAS and KRAS genes mRNA expression were assessed using quantitative real-time polymerase chain reaction techniques. Results Increased relative HRAS mRNA level in blood was found significantly more frequently in the group of smokers (p = 0.008). Patients with squamous cell carcinoma subtypes of NSCLC were more likely to show an overexpression of HRAS gene in blood, but not statistically significant (p = 0.065). In tumor tissue overexpression of HRAS gene was associated with adenocarcinoma subtype (p = 0.049). No statistically significant associations were found for the expression of KRAS with any clinicopathological parameters, except the age of patients, within the study. There were no differences between the relative HRAS and KRAS genes expression levels in blood samples taken from the same patients during the 3 observation points, as well as between blood collected from patients before surgery and tissue samples obtained during operation. Conclusion The potential associations between high HRAS expression levels, age, smoking status and histological type of cancer were observed, which emphasizes the need for further study of the RAS family. Therefore, subsequent research involving larger numbers of patients and a longer follow-up, as well as multicenter study are necessary to confirm our findings. |
| first_indexed | 2024-12-16T15:32:41Z |
| format | Article |
| id | doaj.art-12a399b0c53d4ffc9392f74f8f12fbc0 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-16T15:32:41Z |
| publishDate | 2021-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-12a399b0c53d4ffc9392f74f8f12fbc02022-12-21T22:26:17ZengBMCBMC Cancer1471-24072021-02-0121111310.1186/s12885-021-07858-wClinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findingsMilena Pązik0Katarzyna Michalska1Marta Żebrowska-Nawrocka2Izabela Zawadzka3Mariusz Łochowski4Ewa Balcerczak5Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Cathedral of Laboratory and Molecular Diagnostics, Medical University of LodzLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Cathedral of Laboratory and Molecular Diagnostics, Medical University of LodzLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Cathedral of Laboratory and Molecular Diagnostics, Medical University of LodzLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Cathedral of Laboratory and Molecular Diagnostics, Medical University of LodzDepartment of Thoracic Surgery, Memorial Copernicus Hospital, Medical University of LodzLaboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Cathedral of Laboratory and Molecular Diagnostics, Medical University of LodzAbstract Background The RAS family protooncogenes, including KRAS, NRAS and HRAS, encode proteins responsible for the regulation of growth, differentiation and survival of many cell types. The HRAS and KRAS oncogene mutations are well defined, however, the clinical significance of RAS expressions in non–small-cell lung cancer (NSCLC) is still uncertain. Methods A total of 39 whole blood samples of NSCLC (the investigated group), collected at three points of time: at the time of diagnosis, 100 days and 1 year after the surgery as well as 35 tissue samples obtained during the surgery were included in this study. HRAS and KRAS genes mRNA expression were assessed using quantitative real-time polymerase chain reaction techniques. Results Increased relative HRAS mRNA level in blood was found significantly more frequently in the group of smokers (p = 0.008). Patients with squamous cell carcinoma subtypes of NSCLC were more likely to show an overexpression of HRAS gene in blood, but not statistically significant (p = 0.065). In tumor tissue overexpression of HRAS gene was associated with adenocarcinoma subtype (p = 0.049). No statistically significant associations were found for the expression of KRAS with any clinicopathological parameters, except the age of patients, within the study. There were no differences between the relative HRAS and KRAS genes expression levels in blood samples taken from the same patients during the 3 observation points, as well as between blood collected from patients before surgery and tissue samples obtained during operation. Conclusion The potential associations between high HRAS expression levels, age, smoking status and histological type of cancer were observed, which emphasizes the need for further study of the RAS family. Therefore, subsequent research involving larger numbers of patients and a longer follow-up, as well as multicenter study are necessary to confirm our findings.https://doi.org/10.1186/s12885-021-07858-wLung cancerNSCLCHRASKRASExpression |
| spellingShingle | Milena Pązik Katarzyna Michalska Marta Żebrowska-Nawrocka Izabela Zawadzka Mariusz Łochowski Ewa Balcerczak Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings BMC Cancer Lung cancer NSCLC HRAS KRAS Expression |
| title | Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings |
| title_full | Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings |
| title_fullStr | Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings |
| title_full_unstemmed | Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings |
| title_short | Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings |
| title_sort | clinical significance of hras and kras genes expression in patients with non small cell lung cancer preliminary findings |
| topic | Lung cancer NSCLC HRAS KRAS Expression |
| url | https://doi.org/10.1186/s12885-021-07858-w |
| work_keys_str_mv | AT milenapazik clinicalsignificanceofhrasandkrasgenesexpressioninpatientswithnonsmallcelllungcancerpreliminaryfindings AT katarzynamichalska clinicalsignificanceofhrasandkrasgenesexpressioninpatientswithnonsmallcelllungcancerpreliminaryfindings AT martazebrowskanawrocka clinicalsignificanceofhrasandkrasgenesexpressioninpatientswithnonsmallcelllungcancerpreliminaryfindings AT izabelazawadzka clinicalsignificanceofhrasandkrasgenesexpressioninpatientswithnonsmallcelllungcancerpreliminaryfindings AT mariuszłochowski clinicalsignificanceofhrasandkrasgenesexpressioninpatientswithnonsmallcelllungcancerpreliminaryfindings AT ewabalcerczak clinicalsignificanceofhrasandkrasgenesexpressioninpatientswithnonsmallcelllungcancerpreliminaryfindings |